|  |
| --- |
| **Table A5: Patient Baseline Characteristics, Unmatched, Unfavorable Risk, black men vs white men** |
|  |  | Black | White | P-value | SMD |
|  |  | 5060 | 26833 |  |  |
| Treatment | EBRT+ADT | 2169 (42.9) | 8841 (32.9) | <0.001 | 0.230 |
|  | RP and PLND | 2470 (48.8) | 16143 (60.2) |  |  |
|  | EBRT+BT+ADT | 421 (8.3) | 1849 (6.9) |  |  |
| Facility Type | Community Cancer Program | 397 (7.8) | 2344 (8.7) | <0.001 | 0.216 |
|  | Comprehensive Community Cancer Program | 1954 (38.6) | 12902 (48.1) |  |  |
|  | Academic/Research Program | 2059 (40.7) | 9037 (33.7) |  |  |
|  | Integrated Network Cancer Program | 643 (12.7) | 2547 (9.5) |  |  |
|  | unknown | 7 (0.1) | 3 (0.0) |  |  |
| Geography | New England | 148 (2.9) | 1643 (6.1) | <0.001 | 0.613 |
|  | Middle Atlantic | 778 (15.4) | 3846 (14.3) |  |  |
|  | South Atlantic | 1864 (36.8) | 4864 (18.1) |  |  |
|  | East North Central | 878 (17.4) | 4983 (18.6) |  |  |
|  | East South Central | 458 (9.1) | 2263 (8.4) |  |  |
|  | West North Central | 216 (4.3) | 2829 (10.5) |  |  |
|  | West South Central | 389 (7.7) | 1392 (5.2) |  |  |
|  | Mountain | 50 (1.0) | 1355 (5.0) |  |  |
|  | Pacific | 272 (5.4) | 3655 (13.6) |  |  |
|  | unknown | 7 (0.1) | 3 (0.0) |  |  |
| Insurance | Not Insured | 217 (4.3) | 368 (1.4) | <0.001 | 0.358 |
|  | Private Insurance | 2359 (46.6) | 12373 (46.1) |  |  |
|  | Medicaid | 327 (6.5) | 425 (1.6) |  |  |
|  | Medicare | 1920 (37.9) | 12924 (48.2) |  |  |
|  | Other Government | 146 (2.9) | 399 (1.5) |  |  |
|  | Insurance Status Unknown | 91 (1.8) | 344 (1.3) |  |  |
| Income | $38,000 - $47,999 | 1190 (23.5) | 6223 (23.2) | <0.001 | 0.705 |
|  | $48,000 - $62,999 | 987 (19.5) | 7498 (27.9) |  |  |
|  | $63,000 + | 855 (16.9) | 9601 (35.8) |  |  |
|  | < $38,000 | 2001 (39.5) | 3405 (12.7) |  |  |
|  | unknown | 27 (0.5) | 106 (0.4) |  |  |
| Charleson Deyo Comorbidity Index | 0 | 4114 (81.3) | 23061 (85.9) | <0.001 | 0.128 |
|  | 1 | 804 (15.9) | 3282 (12.2) |  |  |
|  | 2 | 142 (2.8) | 490 (1.8) |  |  |
| Age |  | 62.56 (8.36) | 65.44 (8.20) | <0.001 | 0.348 |
| Risk Cohort | HR | 4006 (79.2) | 20351 (75.8) | <0.001 | 0.080 |
|  | IR | 643 (12.7) | 3898 (14.5) |  |  |
|  | VHR | 411 (8.1) | 2584 (9.6) |  |  |
| Diagnosis to treatment initiation time | 0-90 | 3542 (71.8) | 20692 (79.5) | <0.001 | 0.215 |
|  | >90 | 1142 (23.2) | 3845 (14.8) |  |  |
|  | unknown | 248 (5.0) | 1489 (5.7) |  |  |
| clinical T stage | T1 | 2491 (49.2) | 11598 (43.2) | <0.001 | 0.136 |
|  | T2 | 1423 (28.1) | 7984 (29.8) |  |  |
|  | T3 | 719 (14.2) | 4833 (18.0) |  |  |
|  | T4 | 36 (0.7) | 220 (0.8) |  |  |
|  | unknown | 11 (0.2) | 90 (0.3) |  |  |
|  | X | 380 (7.5) | 2108 (7.9) |  |  |
| clinical Gleason score | <=6 | 133 (2.6) | 597 (2.2) | <0.001 | 0.098 |
|  | 10 | 26 (0.5) | 174 (0.6) |  |  |
|  | 7 | 1068 (21.1) | 5471 (20.4) |  |  |
|  | 8 | 776 (15.3) | 4422 (16.5) |  |  |
|  | 9 | 351 (6.9) | 2475 (9.2) |  |  |
|  | unknown | 2706 (53.5) | 13694 (51.0) |  |  |
| PSA | <10 | 1301 (25.7) | 9841 (36.7) | <0.001 | 0.252 |
|  | >20 | 3117 (61.6) | 13501 (50.3) |  |  |
|  | 10-20 | 539 (10.7) | 2811 (10.5) |  |  |
|  | unknown | 103 (2.0) | 680 (2.5) |  |  |
| *Abbreviations: BT=brachytherapy; EBRT=external beam radiotherapy; RP=Radical Prostatectomy; ADT=androgen deprivation therapy; SMD=Standardized mean difference; CI=Confidence Interval; fIR=favorable intermediate risk; LR=low risk; AfA=African American; Cc=Caucasian* |
| \*ng/ml  |
| \*\*combined Gleason score |